A Prospective, Observational, Single-blinded, Longitudinal MRI Study of Effect of Glatiramer Acetate on Iron Deposition in Patients With Relapsing-remitting Multiple Sclerosis Over 24 Months

Trial Profile

A Prospective, Observational, Single-blinded, Longitudinal MRI Study of Effect of Glatiramer Acetate on Iron Deposition in Patients With Relapsing-remitting Multiple Sclerosis Over 24 Months

Completed
Phase of Trial: Phase IV

Latest Information Update: 22 Mar 2013

At a glance

  • Drugs Glatiramer acetate (Primary)
  • Indications Multiple sclerosis
  • Focus Pharmacodynamics
  • Acronyms GASWI
  • Most Recent Events

    • 01 Feb 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 08 Oct 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top